erlotinib has been researched along with Carcinoma, Non-Small Cell Lung in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Chai, S; Ke, CQ; Lin, G; Tang, C; To, KK; Wang, YZ; Yao, S; Ye, Y; Yin, C | 1 |
| Bryan, MC; Burdick, DJ; Chan, BK; Chen, Y; Dotson, J; Eigenbrot, C; Hanan, EJ; Heald, RA; Heffron, TP; Jackson, PS; La, H; Lainchbury, MD; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Seward, EM; Sideris, S; Tam, C; Wang, S; Yeap, SK; Yen, I; Yin, J; Yu, C; Zilberleyb, I | 1 |
| Bowman, KK; Bryan, MC; Burdick, D; Chan, B; Chan, E; Chen, Y; Clausen, S; Dominguez-Fernandez, B; Eigenbrot, C; Elliott, R; Hanan, EJ; Heald, R; Heffron, TP; Jackson, P; Knight, J; La, H; Lainchbury, M; Malek, S; Mann, S; Merchant, M; Mortara, K; Purkey, H; Schaefer, G; Schmidt, S; Seward, E; Shao, L; Sideris, S; Wang, S; Yeap, K; Yen, I; Yu, C | 1 |
| Almaden, C; Bailey, S; Baxi, S; Behenna, D; Cheng, H; Cho-Schultz, S; Dalvie, D; Dinh, DM; Edwards, MP; Feng, JL; Ferre, RA; Gajiwala, KS; Hemkens, MD; Jackson-Fisher, A; Jalaie, M; Johnson, TO; Kania, RS; Kath, JC; Kephart, S; Lafontaine, J; Liu, KK; Liu, Z; Lunney, B; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Ornelas, MA; Orr, ST; Pairish, M; Planken, S; Ren, S; Richter, D; Ryan, K; Sach, N; Shen, H; Smeal, T; Solowiej, J; Sutton, S; Tran, K; Tseng, E; Vernier, W; Walls, M; Wang, S; Weinrich, SL; Xin, S; Xu, H; Yin, MJ; Zhou, R; Zientek, M | 1 |
| Almaden, C; Bailey, S; Ballard, TE; Behenna, DC; Bernier, L; Cheng, H; Cho-Schultz, S; Dalvie, D; Deal, JG; Dinh, DM; Edwards, MP; Ferre, RA; Gajiwala, KS; Hemkens, M; Johnson, TO; Kania, RS; Kath, JC; Lafontaine, J; Liu, L; Luo, Y; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Orr, ST; Pairish, M; Planken, S; Sach, NW; Shen, H; Shi, M; Solowiej, J; Tran, K; Tseng, E; Vicini, P; Wang, Y; Weinrich, SL; Xin, S; Zhang, C; Zhou, R; Zientek, M | 1 |
| Byczek-Wyrostek, A; Kasprzycka, A; Kitel, R; Rumak, K; Skonieczna, M; Walczak, K | 1 |
| Chaudhari, D; Jain, S; Silakari, O; Singh, PK | 1 |
| Chen, Y; Cheng, Z; Huang, X; Jiang, Y; Qiao, H; Xie, J; Yang, L; Yu, B; Zhao, W; Zhou, W | 1 |
| Alice Nagel, Y; Bischoff, JR; Burger, D; Dietzig, A; Ehler, A; Friess, T; Goergler, A; Herting, F; Hewings, D; Imhoff, MP; Jaeschke, G; Koldewey, P; Kornacker, M; Kuglstatter, A; Kuhn, B; Martoglio, B; Marty, HP; Obst-Sander, U; Pao, W; Raschetti, N; Ricci, A; Rueher, D; Rynn, C; Schaffland, JP; Steiner, S | 1 |
10 other study(ies) available for erlotinib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glycosides; Humans; Marsdenia; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pregnanes; Quinazolines | 2014 |
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.
Topics: Amino Acid Substitution; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; High-Throughput Screening Assays; Humans; Lung Neoplasms; Methionine; Mutation; Protein Kinase Inhibitors; Threonine | 2014 |
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dogs; Drug Design; ErbB Receptors; Gene Knockdown Techniques; Genes, erbB-1; Humans; In Vitro Techniques; Lipids; Lung Neoplasms; Macaca fascicularis; Microsomes, Liver; Models, Molecular; Mutation; Rats; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity; Xenograft Model Antitumor Assays | 2015 |
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Mutant Proteins; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants
Topics: Acrylamides; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dogs; Drug Design; ErbB Receptors; Halogenation; Humans; Lung; Lung Neoplasms; Mice; Models, Molecular; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Pyrrolidines; Rats | 2017 |
Simple 2(5H)-furanone derivatives with selective cytotoxicity towards non-small cell lung cancer cell line A549 - Synthesis, structure-activity relationship and biological evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Furans; Humans; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship | 2018 |
Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Protein Kinase Inhibitors | 2019 |
Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Conformation; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2020 |
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrimidines | 2022 |